Aptose Biosciences Inc (TSE:APS) (NASDAQ:APTO) had its price target lowered by Royal Bank Of Canada to C$16.00 in a report released on Wednesday morning. The firm currently has an outperform rating on the stock.

Aptose Biosciences (TSE:APS) traded up 1.63% during trading on Wednesday, hitting $1.25. 21,600 shares of the stock were exchanged. The firm’s 50-day moving average is $2.22 and its 200 day moving average is $2.93. The firm’s market cap is $16.12 million. Aptose Biosciences has a 52 week low of $1.12 and a 52 week high of $7.24.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Stock Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related stocks with our FREE daily email newsletter.